Stronger together: Coping behaviours and mental health changes of Canadian adolescents in early phases of the COVID-19 pandemic

BMC Public Health, Journal Year: 2023, Volume and Issue: 23(1)

Published: Feb. 13, 2023

The impact of the COVID-19 pandemic and consequent public health restrictions on mental adolescents is global concern. purpose this study was to examine how Canadian coped during early whether different coping methods were associated with changes in from before lockdown response.

Language: Английский

---

Development of an anxiety disorder following an emergency department visit due to cannabis use: a population-based cohort study

EClinicalMedicine, Journal Year: 2024, Volume and Issue: 69, P. 102455 - 102455

Published: Feb. 5, 2024

BackgroundThere is ongoing uncertainty about whether cannabis use increases the risk of developing an anxiety disorder. In this study we estimated having incident healthcare visit for disorder following emergency department (ED) and explored factors associated with increased risk.MethodsWe used health administrative data to perform a population-based cohort all individuals aged 10–105 years no previous visits disorders in Ontario, Canada, between January 2008 March 2019. We compared ED or hospital (primary analysis) additionally outpatient setting (secondary members general population using cumulative incidence functions cause-specific hazard models adjusted relevant confounders.FindingsOur included 12,099,144 without prior care hospital, which 34,822 (0.29%) had due cannabis. Within 3-years cannabis, 12.3% (n = 4294) hospitalization disorder—a 3.7-fold (adjusted Hazard Ratio [aHR] 3.69 95% CI 3.57–3.82) relative (1.2%). secondary analysis, further excluding disorders, 23.6% visit, within 5.6% (aHR 3.88 3.77–2.99). The was higher across age sex strata. However, younger males 5.67 5.19–6.21) greater than women 3.22 2.95–3.52).InterpretationED were disorder, particularly young males. These findings have important clinical policy implications given increasing over time trend towards legalization cannabis.FundingCanadian Institutes Health Research.

Language: Английский

---

Cannabis use in the UK: a quantitative comparison of individual differences in medical and recreational cannabis users

Frontiers in Psychology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 8, 2024

There is a paucity of research, especially in the UK, that investigates individual differences both medical and recreational cannabis users. A cross-sectional survey study design was used to assess users currently living UK. Recreational were invited take part via social media. Medical recruited from Sapphire Clinics, London, which provides treatment with prescribed cannabis-based medicinal products. Demographic data use frequency, as well post-traumatic stress disorder symptoms (PCL-5), depression (Centre for Epidemiological Studies Depression Scale), trait state anxiety (State-Trait Anxiety Inventory), motives [Comprehensive Marijuana Motives Questionnaire (CMMQ)] collected. The Chi-square independent-sample t -tests comparison categorical variables normally distributed continuous variables. Data analyzed using analyses variance (ANOVAs) -tests. Statistical significance considered where value p <0.05. completed by 161 participants. older, consumed more often, had higher “Sleep” motive on CMMQ, prevalence self-reporting current diagnoses neurological problems, mood disorders, disorders ( < 0.05). scores several (e.g., “Enjoyment,” “Coping,” “Experimentation,” “Boredom,” “Celebration”) most common groups “Low Risk,” “Sleep.” no between gender, “Low-Risk” motive, symptoms, scores, self-reported substance use-related past consumption alcohol, tobacco, or caffeine > not only demonstrates difference age motivations but also shows areas potential overlap, including mental health outcomes, use, gender. These UK-specific findings indicate experience anxiety, highlighting need further evaluation anxiogenic/anxiolytic properties cannabis. demonstrate importance researching hold significant implications future clinical practice, legislation.

Language: Английский

---

Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms

Cannabis and Cannabinoid Research, Journal Year: 2021, Volume and Issue: 7(5), P. 706 - 716

Published: Sept. 27, 2021

Introduction: Cannabigerol (CBG), and its precursor before decarboxylation, cannabigerolic acid is sometimes labeled the "mother of all cannabinoids." The purpose present study was to investigate reasons for use self-reported therapeutic effects in CBG-predominant cannabis users. Usage patterns adverse effects, including withdrawal symptoms were also explored. Methods: Cannabidiol-predominant users recruited online complete an survey assessing CBG patterns, conditions treated with (containing >50% CBG), perceived efficacy, associated events, symptoms. One hundred twenty-seven eligible participants (U.S. residents ages 21+ who reported using past 6 months) completed survey. Results: Most samples (n=65; 51.2%) products solely medical purposes (n=46; 36.2% recreational purposes; n=8; 6.3% only, n=8 missing). most common sample treat anxiety (51.2%), chronic pain (40.9%), depression (33.1%), insomnia/disturbed sleep (30.7%). Efficacy highly rated, majority reporting their "very much improved" or "much by CBG. Furthermore, 73.9% claimed superiority over conventional medicines pain, 80% depression, 73% insomnia, 78.3% anxiety. Forty-four percent no 16.5% noting dry mouth, 15% sleepiness, 11.8% increased appetite, 8.7% eyes. Around 84.3% symptoms, difficulties representing frequently endorsed symptom (endorsed two respondents). Conclusions: This first patient date, document efficacy products, particularly anxiety, insomnia. respondents greater pharmacotherapy, a benign event profile negligible establishes that humans are employing suggests cannabis-based should be studied randomized controlled trials.

Language: Английский

---

Opposing retrograde and astrocyte-dependent endocannabinoid signaling mechanisms regulate lateral habenula synaptic transmission

Cell Reports, Journal Year: 2023, Volume and Issue: 42(3), P. 112159 - 112159

Published: Feb. 26, 2023

The lateral habenula (LHb) encodes aversive states, and its dysregulation is implicated in neuropsychiatric disorders, including depression. endocannabinoid (eCB) system a neuromodulatory signaling that broadly serves to counteract the adverse effects of stress; however, CB

Language: Английский

---

Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review

European Child & Adolescent Psychiatry, Journal Year: 2023, Volume and Issue: 33(2), P. 505 - 526

Published: March 3, 2023

A better understanding of the endocannabinoid system and a relaxation in regulatory control cannabis globally has increased interest medicinal use cannabinoid-based products (CBP). We provide systematic review rationale current clinical trial evidence for CBP treatment neuropsychiatric neurodevelopmental disorders children adolescents. search MEDLINE, Embase, PsycINFO, Cochrane Central Register Trials was performed to identify articles published after 1980 about medical purposes individuals aged 18 years or younger with selected conditions. Risk bias quality assessed each article. Of 4466 screened, were eligible inclusion, addressing eight conditions (anxiety (n = 1); autism spectrum disorder 5); foetal alcohol fragile X syndrome 2); intellectual disability mood post-traumatic stress 3); Tourette 3)). Only one randomised controlled (RCT) identified. The remaining seventeen included open-label trial, three uncontrolled before-and-after trials, two case series 11 reports, thus risk high. Despite growing community scientific interest, our identified limited generally poor-quality efficacy Large rigorous RCTs are required inform care. In meantime, clinicians must balance patient expectations available.

Language: Английский

---

Self-Reported Effects of Cannabis on ADHD Symptoms, ADHD Medication Side Effects, and ADHD-Related Executive Dysfunction

Journal of Attention Disorders, Journal Year: 2021, Volume and Issue: 26(6), P. 942 - 955

Published: Oct. 11, 2021

People with ADHD are more likely to use cannabis but little is known about the effects of on symptoms, medication side effects, or ADHD-related executive dysfunction.Students (n = 1,738) completed an online survey containing measures use, perceived symptoms and as well dysfunction.Participants who have used reported that has acute beneficial many (e.g., hyperactivity, impulsivity). Further, they improve most their irritability, anxiety). Finally, frequency was a significant moderator associations between symptom severity dysfunction.Results suggest people may be using self-medicate for frequent mitigate dysfunction.

Language: Английский

---

Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)

Current Rheumatology Reports, Journal Year: 2022, Volume and Issue: 24(7), P. 238 - 246

Published: May 3, 2022

Language: Английский

---

Medicinal cannabis for the treatment of anxiety disorders

Australian Journal of General Practice, Journal Year: 2022, Volume and Issue: 51(8), P. 586 - 592

Published: Aug. 1, 2022

Anxiety is second most common reason for medicinal cannabis prescription in Australia and being treated with both Δ9-tetrahydrocannabinol (THC)-containing cannabidiol (CBD)-dominant products.The aim of this article to summarise recent advances the understanding treating anxiety trends prescribing.Clinical trials laboratory studies provide evidence anxiolytic effects CBD healthy volunteers clinical populations, although current insufficient support as a first-line treatment. The regarding use THC-dominant products ambiguous, exacerbation some individuals relief others. Caution required THC can impair driving cognitive function. Despite lack robust supportive evidence, increasing rapidly, while illicit widely used community self-medicate anxiety. Approximately 17% prescriptions are CBD- dominant liquid (oils), wafers capsules, remainder THC-containing (33%) herbal vaporisation (50%). Medical practitioners should carefully consider potential risks benefits when prescribing disorders 'start low go slow'.

Language: Английский

---

Anxiety Modulation by Cannabinoids—The Role of Stress Responses and Coping

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(21), P. 15777 - 15777

Published: Oct. 30, 2023

Endocannabinoids were implicated in a variety of pathological conditions including anxiety and are considered promising new targets for anxiolytic drug development. The optimism concerning the potentials this system anxiolysis is probably justified. However, complexity mechanisms affected by endocannabinoids, discrepant findings obtained with various experimental approaches makes interpretation research results difficult. Here, we review anxiety-related effects three main interventions used to study endocannabinoid system: pharmacological agents active at endocannabinoid-binding sites present on both cell membrane cytoplasm, genetic manipulations targeting cannabinoid receptors, function-enhancers represented inhibitors degradation transport. Binding-site ligands provide inconsistent because they activate multitude concomitantly. More robust particularly function enhancers, which heighten ongoing activation rather than affecting all indiscriminately. enhancement activity appears ameliorate stress-induced without consistent general. Limited evidence suggests that effect achieved promoting coping styles critical situations. These suggest functional signaling development target stress-related disorders.

Language: Английский

---